Titan Pharmaceuticals Announces Agreement in Principle on Path Forward for Probuphine Clinical StudyMarketwire (Mar 3, 2014)
Marketwire (Dec 23, 2013)
Titan Pharmaceuticals, Inc is a biopharmaceutical company focused in the development of products for the treatment of central nervous system (CNS) diseases.
Friday, Sep 272013, 2:20 PM
Friday, Sep 272013, 2:20 PM| 1 Comment
- Titan Pharmaceuticals (TTNP.OB +16.4%) rallies on huge volume.
- The FDA has granted the company a Type C meeting for November 19 to discuss exactly what went wrong with the Probuphine NDA.
- The company hopes the meeting will provide some "clarity regarding the regulatory path forward" for the buprenorphine implant. (PR)
- The stock collapsed in May when the company received the CRL.
Wednesday, May 12013, 9:56 AMTitan Pharmaceuticals (TTNP.OB -75.9%) loses more than three quarters of its market value after the FDA rejects its experimental opioid addiction treatment Probuphine. The company says it is "extremely surprised and disappointed" — shareholders likely feel the same. (See SA contributor Brian Wilson's opinion piece for more) |Wednesday, May 12013, 9:56 AM| 2 Comments
Monday, Mar 252013, 4:40 PMTitan Pharmaceuticals (TTNP.OB +7.8%) extends gains Monday after rising more than 30% Friday on news the FDA has recommended approval of the company's opioid addiction drug Probuphine. Investors however, are no doubt still stinging from the ~40% dive the stock took last Tuesday. |Monday, Mar 252013, 4:40 PM| Comment!
Friday, Mar 222013, 12:11 PMShares of Titan Pharmaceuticals (TTNP.OB +35%) rise dramatically after the company says the FDA recommends approval for its opioid addiction treatment drug Probuphine. The terms of a licensing agreement announced last year indicate Titan will receive $50M from its commercialization partner Braeburn Pharmaceuticals upon FDA approval. |Friday, Mar 222013, 12:11 PM| 2 Comments
Tuesday, Mar 192013, 9:34 AMTitan Pharmaceuticals' (TTNP.OB) Probuphine treatment for addiction to heroin and opioid painkillers has shown to be more effective than a placebo, but the data suggests that the dosages given might need to be higher, say FDA staff, who also raise safety concerns. The comments come ahead of a review on Thursday by an advisory panel about whether to recommend of approval for Probuphine. |Tuesday, Mar 192013, 9:34 AM| 7 Comments
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.